Jack Wallace
Stock Analyst at Guggenheim
(2.94)
# 1,628
Out of 4,749 analysts
22
Total ratings
57.89%
Success rate
7.96%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $233.26 | +6.75% | 4 | Oct 1, 2024 | |
| WW WW International | Maintains: Buy | $12 → $6 | $1.08 | +455.56% | 3 | Aug 2, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $37.28 | -54.40% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $5.63 | +148.67% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $201.36 | +9.26% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $28.46 | +40.55% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $10.78 | +827.64% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $22.66 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $233.26
Upside: +6.75%
WW International
Aug 2, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $1.08
Upside: +455.56%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $37.28
Upside: -54.40%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $5.63
Upside: +148.67%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $201.36
Upside: +9.26%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $28.46
Upside: +40.55%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $10.78
Upside: +827.64%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $22.66
Upside: -